New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
08:50 EDTMDCOThe Medicines Co. announces EMA accepts MAA for oritavancin
The Medicines Company announced that the European Medicines Agency has accepted for review a marketing authorization application for the investigational intravenous antibiotic, oritavancin, for the treatment of complicated skin and skin tissue infections caused by susceptible gram-positive bacteria, including by methicillin-resistant Staphylococcus aureus, administered as a single dose. The oritavancin MAA is based on data from two Phase 3 clinical trials, SOLO I and SOLO II. These Phase 3 trials evaluated the efficacy and safety of a single 1200 mg dose of oritavancin compared to 7 to 10 days of twice-daily vancomycin in adults with cSSTI, including infections caused by MRSA. The combined SOLO studies were conducted in 1,959 patients with 405 of the patients suffering from a cSSTI with a documented MRSA infection. The acceptance of the MAA marks the beginning of the review process in the European Union for oritavancin. Oritavancin is also under review by the US Food and Drug Administration in the U.S.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
07:07 EDTMDCOThe Medicines Co. settles with Sun, says can market generic Angiomax
The Medicines Company announced that it has settled its litigation with Sun Pharmaceutical Industries and certain of its subsidiaries relating to MDCO’s U.S. Patent No. 7,582,727 and U.S. Patent No. 7,598,343 covering Angiomax, bivalirudin. As a result of the settlement, MDCO will permit a Sun Pharma subsidiary to market a generic bivalirudin product in the United States on June 30, 2019, or earlier in certain limited circumstances. This settlement validates MDCO’s patents while allowing a Sun Pharma subsidiary to enter the market with its generic product. The agreement will be submitted to the applicable governmental agencies for review.
March 30, 2015
07:05 EDTMDCOThe Medicines Co. receives EC approval for three hospital acute care products
Subscribe for More Information
March 27, 2015
08:44 EDTMDCOThe Medicines Co. has a conference call hosted by JPMorgan
Subscribe for More Information
06:08 EDTMDCOThe Medicines Co. assumed with a Neutral at Citigroup
Target $30.
March 25, 2015
07:12 EDTMDCOAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
March 20, 2015
10:00 EDTMDCOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
March 19, 2015
16:06 EDTMDCOThe Medicines Co. initiated with a Neutral at Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use